Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals has announced that its partner GlaxoSmithKline (GSK) has voluntarily suspended enrollment of ongoing GSK2251052 (GSK '052) Phase I and II clinical trials.
Subscribe to our email newsletter
GSK has identified microbiological finding in a small number of patients in the Phase IIb trial of GSK ‘052 for the treatment of complicated urinary tract infections (cUTI).
The company is in the process of obtaining additional information to better understand the data and will not resume the trials until it has concluded its investigation.
GSK will determine next steps regarding the future development of GSK ‘052, upon completion of the review, the company said.
GSK is currently conducting a Phase IIb trial of GSK2251052 for the treatment of complicated urinary tract infections, a Phase IIb study for complicated intra-abdominal infections and two Phase II studies in healthy volunteers.
People currently enrolled in the ongoing studies may continue at the discretion of the investigator.
Anacor CEO David Perry said they respect GSK’s decision to pause enrollment in the current studies as they fully investigate the microbiology finding in the Phase IIb cUTI patients.